Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.
Fiche publication
Date publication
juin 2015
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Luthra P, Peyrin-Biroulet L, Ford AC
Lien Pubmed
Résumé
Anti-integrin antibodies are effective therapies for Crohn's disease (CD) and ulcerative colitis (UC). However, these drugs carry theoretical risks of opportunistic infection and malignancy.
Mots clés
Adult, Antibodies, Monoclonal, adverse effects, Antibodies, Monoclonal, Humanized, immunology, Clinical Trials as Topic, Colitis, Ulcerative, drug therapy, Crohn Disease, drug therapy, Humans, Inflammatory Bowel Diseases, drug therapy, Integrins, administration & dosage, Natalizumab, Neoplasms, chemically induced, Opportunistic Infections, chemically induced, Prospective Studies
Référence
Aliment. Pharmacol. Ther.. 2015 Jun;41(12):1227-36